Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: de Novo Coronary Lesions Clear all
Completed Not applicable Interventional

The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions

NCT00217269
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Artery Stenting
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 24, 2026, 5:46 AM EDT
Not listed Not applicable Interventional Results available

Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems

NCT00715884
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Atherosclerosis
Interventions
CYPHER® ELITE™ Sirolimus-Eluting Stent System, CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions

NCT00371475
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté-SR, TAXUS™ Express
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Sacramento, California • Newark, Delaware • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

Resolute Integrity US Extended Length Sub-Study(RI US XL)

NCT01913600
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

NCT01500434
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
21
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions

NCT00232752
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
4.0 CYPHER Sirolimus-Eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

BIOHELIX-I Bare Metal Stent Study

NCT01612767
View directory record Official record
Conditions
Coronary Arteries Disease
Interventions
PRO-Kinetic Energy Stent
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Phoenix, Arizona • Concord, California • Mission Viejo, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Jul 24, 2026, 5:46 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions

NCT00232739
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CYPHER Sirolimus-eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2010 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

NCT00165035
View directory record Official record
Conditions
Coronary Disease
Interventions
CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Jul 24, 2026, 5:46 AM EDT
Completed No phase listed Observational Results available

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT04175626
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
Interventions
Orsiro DES
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
33
States / cities
Fairhope, Alabama • Concord, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions

NCT01092416
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Diamondback 360 Orbital Atherectomy System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
51
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jul 24, 2026, 5:46 AM EDT
Recruiting Not applicable Interventional

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

NCT06271590
View directory record Official record
Conditions
Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Interventions
Sirolimus Drug Coated Balloon, Drug eluting stents (DES)
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
24
States / cities
Gilbert, Arizona • Los Angeles, California • Clearwater, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

The OMEGA Clinical Trial

NCT01419171
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
OMEGA™ Monorail Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
22
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Loma Linda, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)

NCT00232765
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CYPHER Sirolimus-Eluting Stent, Uncoated BX VELOCITY Balloon-Expandable Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

TAXUS PERSEUS Workhorse

NCT00484315
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
82
States / cities
Birmingham, Alabama • Bakersfield, California • La Jolla, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

NIRTRAKS Post-Market Study (NIRTRAKS)

NCT02455804
View directory record Official record
Conditions
de Novo Stenotic Lesions in Native Coronary Arteries
Interventions
Stenting procedure
Device
Lead sponsor
Medinol Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Jul 24, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels

NCT01498692
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • Ocala, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 24, 2026, 5:46 AM EDT
Recruiting Not applicable Interventional

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

NCT06959524
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Interventions
Drug Eluting Balloon, Drug eluting stent, Plain old balloon angioplasty
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
43
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 24, 2026, 5:46 AM EDT